# OnCo record echelon-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/echelon-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "echelon-2", "NCT01777152" ;
  schema:name "ECHELON-2"@en ;
  schema:description "ECHELON-2 was the first trial in decades to improve on CHOP chemotherapy for T-cell lymphoma: swapping vincristine for the antibody-drug conjugate brentuximab vedotin helped patients live longer, especially those with anaplastic large cell lymphoma."@en ;
  schema:url <https://onco.cc/trials/echelon-2/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01777152> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/vincristine/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/takeda/> ;
  onco:people <https://onco.cc/people/steven-horwitz/> .